POS1121 THE USE OF THE CD3/CD19 T CELL ENGAGER BLINATUMOMAB IN SEVERE SYSTEMIC SCLEROSIS: A CASE SERIES
M. Scherlinger(Inserm), J. Sibilia(Université de Strasbourg), A. Moltó(Université de Strasbourg), Célestine Simand(Hôpitaux Universitaires de Strasbourg), A. Guffroy(Université de Strasbourg), Emmanuel Chatelus(Laboratoire National de Référence), Justine Decroocq(Centre National de la Recherche Scientifique), E. Sebbag(Hôpital d'Hautepierre), Thierry Martin(Western Infirmary), Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), J. Avouac(Hôpital Cochin), A. El Aatmani(Hôpital Civil, Strasbourg), Yannick Dieudonné(Inserm)
Cited by 3
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432